Selecting from IL-23s

Tildrakizumab (Ilumya) is a brand-name biologic medication that’s used to treat moderate to severe plaque psoriasis. This drug is an interleukin (IL-23) inhibitor that’s very effective and works long-term to control the symptoms of psoriasis. Tildrakizumab can help a wide range of psoriasis patients (even those with inflammatory bowel disease, IBD), including those with other health complications. A dermatologist can prescribe the medication, which is injected under your skin (subcutaneous injection) once every 12 weeks.

Next Video

Tildrakizumab candidates

Long-term use of interleukin-23 (IL-23) psoriasis therapies
This physician-led video initiative explores community experience with the long-term use and effect of interleukin-23 (IL-23) psoriasis therapies.